Targeting NF-κB signaling by Calebin A, a compound of turmeric, in multicellular tumor microenvironment: potential role of apoptosis induction in CRC cells by Buhrmann, Constanze et al.
biomedicines
Article
Targeting NF-κB Signaling by Calebin A,
a Compound of Turmeric, in Multicellular Tumor
Microenvironment: Potential Role of Apoptosis
Induction in CRC Cells
Constanze Buhrmann 1, Parviz Shayan 2, Kishore Banik 3, Ajaikumar B. Kunnumakkara 3,
Peter Kubatka 4 , Lenka Koklesova 5 and Mehdi Shakibaei 1,*
1 Musculoskeletal Research Group and Tumor Biology, Chair of Vegetative Anatomy, Institute of Anatomy,
Faculty of Medicine, Ludwig-Maximilian-University Munich, Pettenkoferstrasse 11,
D-80336 Munich, Germany; constanze.buhrmann@med.uni-muenchen.de
2 Department of Parasitology, Faculty of Veterinary Medicine, University of Tehran, Tehran 141556453, Iran;
pshayan@ut.ac.ir
3 Cancer Biology Laboratory & DBT-AIST International Center for Translational and Environmental
Research (DAICENTER), Department of Biosciences & Bioengineering, Indian Institute of Technology
Guwahati, Assam 781039, India; kishore.banik@iitg.ac.in (K.B.); kunnumakkara@iitg.ac.in (A.B.K.)
4 Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava,
03601 Martin, Slovakia; peter.kubatka@uniba.sk
5 Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava,
036 01 Martin, Slovakia; koklesova.lenka@gmail.com
* Correspondence: mehdi.shakibaei@med.uni-muenchen.de; Tel.: +49-89-2180-72624; Fax: +49-89-2180-72625
Received: 6 July 2020; Accepted: 20 July 2020; Published: 22 July 2020


Abstract: Increasing lines of evidence suggest that chronic inflammation mediates most chronic
diseases, including cancer. The transcription factor, NF-κB, has been shown to be a major regulator of
inflammation and metastasis in tumor cells. Therefore, compounds or any natural agents that can
inhibit NF-κB activation have the potential to prevent and treat cancer. However, the mechanism
by which Calebin A, a component of turmeric, regulates inflammation and disrupts the interaction
between HCT116 colorectal cancer (CRC) cells and multicellular tumor microenvironment (TME) is
still poorly understood. The 3D-alginate HCT116 cell cultures in TME were treated with Calebin A,
BMS-345541, and dithiothreitol (DTT) and examined for invasiveness, proliferation, and apoptosis.
The mechanism of TME-induced malignancy of cancer cells was confirmed by phase contrast, Western
blotting, immunofluorescence, and DNA-binding assay. We found through DNA binding assay,
that Calebin A inhibited TME-induced NF-κB activation in a dose-dependent manner. As a result
of this inhibition, NF-κB phosphorylation and NF-κB nuclear translocation were down-modulated.
Calebin A, or IκB-kinase (IKK) inhibitor (BMS-345541) significantly inhibited the direct interaction
of nuclear p65 to DNA, and interestingly this interaction was reversed by DTT. Calebin A also
suppressed the expression of NF-κB-promoted anti-apoptotic (Bcl-2, Bcl-xL, survivin), proliferation
(Cyclin D1), invasion (MMP-9), metastasis (CXCR4), and down-regulated apoptosis (Caspase-3) gene
biomarkers, leading to apoptosis in HCT116 cells. These results suggest that Calebin A can suppress
multicellular TME-promoted CRC cell invasion and malignancy by inhibiting the NF-κB-promoting
inflammatory pathway associated with carcinogenesis, underlining the potential of Calebin A for
CRC treatment.
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1. Introduction
Colorectal cancer (CRC) is the third most common cancer occurring globally and is among the five
leading causes of deaths due to cancer in the world [1]. It is now recognized that CRC is a multifactorial
process involving risk factors such as environment, lifestyle, and genetic predisposition [2,3] and that
CRC is a multi-stage disease that is promoted by chronic, low-grade inflammation of the bowel [4].
Recent research has shown that inflammation in the tumor cells of CRC and its immediate
surroundings, known as the TME, plays a crucial role in the malignant progression of CRC [5,6].
Here, under the influence of cytokines, growth factors, and chemotactic stimuli, the tumor cells recruit
stromal fibroblasts and transform them into malignant ones and create an environment that is capable
of supporting the progression of tumor malignancy [5,7]. As a matter of fact, the transformed stromal
fibroblasts secrete tumor-stimulating factors and play a vital role in transforming the extracellular
matrix to facilitate tumor invasion and metastasis [8]. In addition to the transformed stromal fibroblasts,
immune cells, such as B- and T-lymphocytes, are also essential to promote tumor malignancy and
evade the immunological response by producing reactive oxygen species and inflammatory cytokines,
thereby stimulating inflammatory cascades in the cancer cells [9–11].
The transcription factor nuclear factor-kappaB (NF-κB) is a major regulator of inflammation and
has been found to be frequently activated as a stress responder and stimulates low-grade chronic
inflammation [12,13]. In its inactive form, NF-κB is found in the cytoplasm of various cells as homo-
and/or heterotrimers with p50, p52, c-Rel, RelA (p65) and RelB subunits, and the activation of the
pathway is divided into canonical and non-canonical signaling pathways [14,15]. The activation
of canonical NF-κB signaling is strictly regulated by cytoplasmic inhibitory proteins of the IκB
family [16,17], which in turn are regulated by IκB kinase (IKK) complexes (IKKα, IKKβ, IKKγ) [15,18].
NF-κB is crucial for biological processes that regulate cell growth, survival and tissue
development [14]. It has been shown that the constitutive activation of NF-κB in cancer stimulates
cancer cell progression [19–21]. Hereby, NF-κB is closely involved in the suppression of cellular
apoptosis and mediates its actions through the up-regulation of anti-apoptotic genes such as B cell
lymphoma extra-large (Bcl-xL), cellular apoptosis inhibitors (cIAPs), survivin, B-cell lymphoma (Bcl-2),
X-linked inhibitor of apoptosis protein (XIAP), and caspase-8/FAS-associated death domain-like IL-1β
converting enzyme inhibiting protein [15,22,23].
NF-κB activation has been shown to stimulate the inflammatory response of TME and promote
cancer by supporting immune modulations, tumor cell survival, and paracrine signaling of
pro-inflammatory cytokines in the TME [11,24]. Furthermore, the activation of autocrine and paracrine
signals from members of the tumor necrosis factor (TNF) family has a major impact on invasion and
metastasis of cancer cells [25–28]. Studies have shown that lymphocytes that secrete TNF-β into the
TME stimulates cancer progression by activation and interaction via the TNF-receptor/NF-κB signaling
pathway [29]. Therefore, targeting the NF-κB signaling pathway has also revealed to be a promising
new therapeutic approach in CRC, which could ultimately lead to the better management of this
deadly disease [30].
In the search for novel therapeutic agents that target the development and progression of cancer,
natural products have become the focus of scientists because they have a multi-targeting potential
and can overcome the disadvantages of monotherapy such as side effects [31] and drug resistance [32].
In fact, a number of plant-derived products have been identified that could interact, regulate, and thus
target the TME [33]. The natural compound Calebin A is a non-curcuminoid [34] derived from the
rhizome of medicinal turmeric (Curcuma longa L. Zingiberaceae), which is widely used in herbal medicinal
applications [35–37]. Calebin A has been shown to exert anti-inflammatory and anti-tumor properties by
the induction of apoptosis and modulating different signaling pathways [e.g., mitogen-activated protein
kinase (MAPK), extracellular signal-regulated kinase (ERK), p38, Jun N-terminal kinase (JNK)] in
gastric cancer and neurofibroma [38,39]. Several in vitro studies have revealed that Calebin A repressed
the NF-κB signaling pathway in different cancer cell lines [37]. Recent studies have delineated that
Calebin A possesses immense potential to suppress the tumor progression in CRC [25,40]. Calebin A
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suppressed not only pro-inflammatory cytokine TNF-β-induced NF-κB pathway activation, inhibiting
proliferation, migration, and stimulated apoptosis in CRC cells [25,40], but also chemosensitized the
CRC cells further towards 5-fluorouracil [40].
Since paracrine interaction in the TME plays a crucial role in stimulating the tumor progression
process linked with apoptosis inhibition, in the present study we investigated the potential role of
Calebin A in targeting the NF-κB signaling pathway to suppress the cross-talk in the TME and to
stimulate apoptosis in CRC in a multicellular pro-inflammatory TME, in vitro.
2. Materials and Methods
2.1. Antibodies and Chemicals
Anti-phospho-p65-NF-κB, anti-p65-NF-κB, anti-matrix metalloproteinase 9 (MMP-9),
anti-chemokine receptor type 4 (CXCR4), anti-cyclin D1, anti-survivin, anti-PARP, and
anti-cleaved-Caspase-3 were purchased from R&D Systems (Heidelberg, Germany). Anti-Bcl-2 and
anti-Bcl-xL were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rhodamine-coupled
secondary antibodies for immunofluorescence were from Dianova (Hamburg, Germany). MTT reagent
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), 4′,6-diamidino-2-phenylindole (DAPI),
BMS-345541, and anti-β-Actin were from Sigma-Aldrich (Taufkirchen, Germany). Calebin A was a
kind gift from Sabinsa Corporation (East Windsor, NJ, USA) and was prepared as a 10.000 µM stock
solution in DMSO. For the experiments, the Calebin A stock solution was further diluted in the cell
culture medium and the final concentration of dimethyl sulfoxide (DMSO) did not exceed 0.1%.
2.2. Cells and Cell Culture Conditions
HCT116, a CRC cell line, and MRC-5, a normal human fibroblast cell line, were acquired from
the European Collection of Cell Cultures (Salisbury, UK). CRC and MRC-5 cells were cultivated as
monolayers under standard conditions (37 ◦C, 5% CO2) with whole-cell culture growth medium (10%
fetal calf serum (FCS)) as described above [41] and passaged when cells reached 70–80% confluency.
The human T-lymphocyte cell line (Jurkat cells) was obtained from the Leibniz Institute (DSMZ-German
Collection of Microorganisms and Cell Cultures), and the cells were cultivated in suspension with a
whole-cell culture growth medium [42].
2.3. Experimental Study Design
In this study, we established a multicellular pro-inflammatory 3-dimensional (3D) TME similar to
an in vivo TME to investigate the effect of Calebin A on the suppression of TME cross-talk (Figure 1).
Biomedicines 2020, 8, x FOR PEER REVIEW 3 of 17 
progression in CRC [25,40]. Calebin A suppressed not only pro-inflammatory cytokine TNF-β-
induced NF-B pathway activation, inhibiting proliferation, migration, and stimulated apoptosis in 
CRC cells [25,40], but also chemosensitized the CRC cells f rther towards 5-fluorouracil [40]. 
Since paracrine interaction in the TME lays a crucial role in stimulating the tu or progression 
process linked with apoptosis inhibition, in the present study we investigated the potential role of 
Calebi  A in targeting the NF-B signaling pathway to suppress the cross-talk in the TME and to 
stimulate apoptosis in CRC in a multicellular pro-inflammatory TME, in vitro. 
2. Materials and Methods 
.1. Antibodies and Chemicals 
Anti-phospho-p65-NF-B, anti-p65-NF-B, anti-matrix metalloproteinase 9 (MMP-9), anti-
chemokine receptor type 4 (CXCR4), anti-cyclin D1, anti-survivin, anti-PARP, and anti-cleaved-
Caspase-3 were purchased from R&D Systems (Heidelberg, Ger any). Anti-Bcl-2 and anti-Bcl-xL 
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rhodamine-coupled 
secondary antibodies for immunofluorescence were from Dianova (Hamburg, Germany). MTT 
reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), 4′,6-diamidino-2-
phenylindole (DAPI), BMS-345541, and anti-β-Actin were from Sigma-Aldrich (Taufkirchen, 
Germany). Calebin A was a kind gift from Sabinsa Corporation (East Windsor, NJ, USA) and was 
prepared as a 10.000 µM stock solution in DMSO. For the experiments, the Calebin A stock solution 
was further diluted in the cell culture medium and the final concentration of dimethyl sulfoxide 
(DMSO) did not exceed 0.1%. 
2.2. Cells and Cell Culture Conditions 
HCT116, a CRC cell line, and MRC-5, a normal human fibroblast cell line, were acquired from 
the European Collection of Cell Cultures (Salisbury, UK). CRC and MRC-5 cells were cultivated as 
monolayers under standard conditions (37 °C, 5% CO2) with whole-cell culture growth medium (10% 
fetal calf serum (FCS)) as described above [41] and passaged when cells reached 70–80% confluency. 
The human T-lymphocyte cell line (Jurkat cells) was obtained from the Leibniz Institute (DSMZ-
German Collection of Microorganisms and Cell Cultures), and the cells were cultivated in suspension 
with a whole-cell culture growth medium [42]. 
2.3. Experimental Study Design 
In this study, we established a multicellular pro-inflammatory 3-dimensional (3D) TME similar 
to an in vivo TME to investigate the effect of Calebin A on the suppression of TME cross-talk (Figure 
1). 
 
Figure 1. Schematic model showing the experimental setup of multicellular pro-inflammatory TME 
culture conditions. 
For the "multicellular pro-inflammatory TME", MRC-5 cells (normal stromal fibroblasts) were seeded 
in a Petri dish (3000 cells/cm2) with a normal cell culture growth medium for 24 h to adhere to the 
bottom of the Petri dish. Next, 3D-alginate bead cultures of HCT116 CRC cells were established as 
Figure 1. Schematic model showing the experimental setup of multicellular pro-inflammatory TME
culture conditions.
Biomedicines 2020, 8, 236 4 of 17
For the “multicellular pro-inflammatory TME”, MRC-5 cells (normal stromal fibroblasts) were
seeded in a Petri dish (3000 cells/cm2) with a normal cell culture growth medium for 24 h to adhere to
the bottom of the Petri dish. Next, 3D-alginate bead cultures of HCT116 CRC cells were established as
described below. To create the "multicellular pro-inflammatory TME", HCT116 in 3D-alginate beads
and T-lymphocytes (10.000/mL) was added to the Petri dishes containing the MRC-5 fibroblast cells
and co-cultured in 3% FCS culture growth medium. For a “basal control” HCT116 CRC cells were
cultivated in 3D-alginate beads alone. For the experiments, the multicellular pro-inflammatory TME
cultures and HCT116 cultures of the basal control were cultivated either alone or in combination
dose-dependently with Calebin A (1, 5 µM) or with BMS-345541 (5, 10 µM).
2.4. Alginate Culture
HCT116 CRC cells (1 × 106/mL) were suspended in sterile alginate solution (2% in 0.15 M NaCl,
stirred for 2 h at ambient temperature) and a 3D-alginate bead culture was prepared as described
in detail [41,43]. Briefly, the HCT116 cell/alginate solution was added dropwise to a CaCl2 solution
(100 mM). After a 10-minute polymerization of the drops to beads, the beads were washed 3 times
with NaCl solution (0.15 M), once with a whole-cell culture medium (10% FCS) and before starting the
experiments, the beads were incubated for 1 h with a serum-starved medium (3% FCS).
2.5. Vitality and Proliferation
The vitality and proliferation of HCT116 cells in alginate beads from TME cultures was investigated
using the MTT test as described previously [27]. In short, HCT116 cells were retrieved from the alginate
by dissolving for 15 min in sterile 55 mM sodium citrate solution. After continuous washing with
Hank’s balanced salt solution, cells were suspended in modified MTT culture medium (without phenol
red, without vitamin C, 3% FCS), 100 µL cell suspension/well distributed to a 96-well plate, and 10 µL
MTT solution (5 mg/mL) added to each well. After 3 h incubation the reaction was blocked by adding
100 µL MTT-solubilization solution (10% Triton x-100/acidic isopropanol) to each well and samples
incubated overnight at 37 ◦C. Finally, metabolically active cancer cells were determined by measuring
the Optical Density at 550 nm (OD550) using a revelation 96-well multiscanner plate ELISA reader
(Bio-Rad Laboratories Inc. Munich, Germany).
2.6. Colonosphere Formation and Invasion
The colonosphere formation and invasion capacity of HCT116 in 3D-alginate beads in TME culture
were investigated as previously described [25]. For colonosphere formation, 25 microscopic fields
were evaluated by light microscopy (Zeiss, Oberkochen Germany) and for colony formation, invaded
and newly adhering colonies were stained with toluidine blue and quantified by counting all colonies
under the light microscope (Zeiss, Oberkochen Germany) and the images were digitally stored.
2.7. Immunofluorescence
The “multicellular pro-inflammatory TME” described above was modified for immunofluorescence
examination. HCT116 CRC cells were seeded in a monolayer on glass plates (5000/glass plate),
MRC-5 fibroblasts were seeded separately (3000 cells/cm2) in Petri dishes, and cells were cultivated
in a whole-cell culture growth medium (10% FCS) for 24 h to allow adherence. Multicellular
pro-inflammatory TME cultures were established by placing HCT116-containing glass plates on a steel
mesh bridge in the petri dishes containing the stroma fibroblasts and adding T-lymphocytes (20,000/mL)
to the cultures. To allow the development of the TME, the cultures were cultured in a serum-starved
medium for 24 h before starting the tests. The “basal control” held only HCT116 in the monolayer culture
on glass plates (5000/glass plate). For the experiments, the multicellular pro-inflammatory TME cultures
and basal control HCT116 cultures were either cultured alone or in combination dose-dependently
with Calebin A (1, 5 µM) or with BMS-345541 (5, 10 µM). Immunofluorescence investigation of NF-κB
expression in HCT116 CRC cells in TME cultures was performed as previously described [40]. In short,
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after 10 min methanol fixation, HCT116 were washed twice with Hank’s balanced saline solution and
incubated overnight (4 ◦C) with primary antibodies (1:80) in a humid chamber. After additional washing
with Hank’s balanced saline solution the samples were incubated for 2 h with rhodamine coupled
secondary antibodies (1:100) and 15 min with DAPI to stain cell nuclei. Finally, the samples were
embedded with Fluoromount (Sigma-Aldrich, Taufkirchen, Germany), the images were acquired with
a Leica DM2000 microscope (Wetzlar, Germany) and stored digitally. Quantification of the expression
of NF-κB and apoptotic nuclei were performed by counting 600–800 cells in 20 microscopic fields.
2.8. Western Blotting Investigations
Immunoblotting was performed on HCT116 beads from TME cultures as described in detail [41].
In short, HCT116 were retrieved from alginate beads by dissolving in 55 mM sodium citrate solution for
15 min and subsequent washing with Hank’s solution. Samples were lysed (50 mM Tris/HCl, pH 7.2/150
mM NaCl/(v/v) Triton X-100/1 mM sodium orthovanadate/50 mM sodium pyrophosphate/100 mM
sodium fluoride/4 µg/mL pepstatin A/1 mM PMSF) for 30 min on ice to extract whole-cell proteins.
Protein content was measured with the bicinchoninic acid system (Uptima, France) using bovine
serum albumin (BSA) as standard, proteins reduced with 2-mercaptoethanol and total protein
concentrations adjusted (500 ng per lane total protein). After separation of proteins with sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), proteins were blotted onto a nitrocellulose
membrane using a transblot apparatus (Bio-Rad, Munich). Membranes were incubated overnight
(4 ◦C) with primary antibodies (1:10.000) and after subsequent washing, incubated for 2 h with
alkaline-phosphatase coupled secondary antibodies (1:10.000). Finally, specific binding was detected
using nitro blue tetrazolium and 5-bromo-4-chloro-3-indoyl-phosphate (VWR, Darmstadt, Germany)
and bands quantified using the Quantity One program (Bio-Rad, Munich). β-Actin was used to
normalize samples to control.
2.9. DNA-Binding Assay
Nuclear extracts of HCT116 CRC cells from multicellular pro-inflammatory TME cultures were
prepared to further clarify the effect of Calebin A on p65-NF-κB binding to DNA. HCT116 cultured in
multicellular pro-inflammatory TME or as a basal control were obtained from alginate, the cytoplasm
was extracted with cytoplasm extraction buffer and the obtained nuclei were either left untreated
and/or treated with Calebin A (1, 2, 5, 10 µM) for 30 min in a dose-dependent manner. In an additional
approach, HCT116 cells were cultured in multicellular pro-inflammatory TME cultures or as basal
controls, and the extracted nuclei were either left untreated and/or treated with Calebin A (5 µM), DTT
(5 mM) alone or in combination for 1 h. Finally, nuclear extracts were prepared, proteins separated by
SDS-PAGE and blotted on nitrocellulose membranes as described above.
2.10. Statistical Evaluation
A Wilcoxon–Mann–Whitney test was used for statistical evaluation. The samples were presented
as mean ± SD or SEM and compared by one-, two- or three-way ANOVA using SPSS Statistics if the
normality test was passed (Kolmogorov–Smirnov test). A significant difference was considered with a
p-value of < 0.05.
3. Results
In the current study, we investigated the capacity of Calebin A in targeting the NF-κB
signaling pathway and the NF-κB-regulated biomarker gene expression promoted by multicellular
pro-inflammatory TME (Figure 1).
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3.1. Calebin A Suppresses Proliferation Promoted by TME Cultures in 3D-Alginate CRC Cells
Since the pro-inflammatory transcription factor NF-κB is involved in cell survival and cell
proliferation [44,45], we investigated the effect of Calebin A or BMS-345541 on the proliferation of
HCT116 CRC cell lines using the MTT method. We used BMS-345541, a specific inhibitor of the
IKK complex, which can specifically suppress NF-κB activation promoted by various stimuli [46].
HCT116 cells were left untreated or treated with Calebin A, or BMS-345541 and cell proliferation was
evaluated by MTT assay as described in Materials and Methods. Multicellular pro-inflammatory TME
enhanced the proliferation of HCT116 cells significantly compared to the control (Figure 2). In contrast,
Calebin A, similar to BMS-345541, suppressed TME-enhanced proliferation of CRC cells in 3D alginate
tumor cultures in a dose-dependent fashion. TME by itself increased the cell proliferation by more than
double compared to the basal control, enhancing it by 130%. In contrast, the treatment of TME cultures
with Calebin A or BMS-345541 significantly reduced the proliferation of CRC cells in a dose-dependent
manner, compared to the TME control cultures, by around 41% and 59% in Calebin A (1, 5 µM) and by
49% and 81% in BMS-345541 (5, 10 µM), respectively (p < 0.05) (Figure 2). Altogether, these results
suggest that the multicellular pro-inflammatory TME, which significantly favored the proliferation
of HCT116 CRC, and the IKK inhibitor (BMS-345541), similar to Calebin A, blocked the stimulation
effects of the TME.
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Figure 2. Effect of Calebin A (CA) or specific IKK inhibitor BMS-345541 on the proliferation of CRC
cells: Serum starved HCT116 cells in alginate beads from the basal control and multicellular TME
cultures were treated as described i Materials an Methods. Cell pr liferation was analyzed with
the MTT method. All experiments were performe at least three times. p < 0.05 (*) and p < 0.01 (**)
indicate a significant difference compared to the control group.
3.2. Calebin A Suppresses Invasion and Colony Formation Ability, Promoted by TME in 3D-Alginate
CRC Cells
Colony formation and invasion studies, which more accurately reflect the situation in vivo, were
carried out as described in Materials and Methods. As demonstrated in Figure 3A,B, multicellular
pro-inflammatory TME markedly promoted tumor cell migration and colony formation in CRC alginate
cultures compared to the basal control. In contrast, Calebin A, similar to BMS-345541 dose-dependently
blocked colony formation and invasion of HCT116 cells in alginate TME cultures. At the dose 5 µM
Calebin A and 10 µM, BMS-345541 colony formation was decreased by 72% and by 57%, respectively,
compared to the untreated TME control (Figure 3A,B).
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Figure 3. Effects of Calebin A (CA) or specific IKK inhibitor BMS-345541 on colonosphere formation
and invasion in of CRC cells: Serum starved HCT116 cells in alginate (stars) were treated as described
in Materials and Methods. Colonosphere formation (A) and invasion (B) were analyzed by light
microscopy after 10 days. All experiments were performed at least three times. The number of
colonospheres (arrows) was quantified by counting 25 different microscopic fields, and the number
of attached colonies was quantified in each well. p < 0.05 (*) and p < 0.01 (**) indicate a significant
difference compared to the control group. Magnification A: × 24, bar = 0.2 mm.
3.3. Calebin A Decreases TME-Induced Activation and Nuclear Translocation of p65-NF-κB in CRC Cells
We further investigated whether Calebin A modulates the TME-promoted nuclear translocation of
p65-NF-κB. It is known that cytokines in the pr -inflammatory TME induce th activati n and
phosphorylation of p65-NF-κB, which is nec ssary for its transcriptio al activity so that after
s r l ti the p65 subunit is translocated into the nucleus of cells [47]. In the untre ted
multicellular pro-inflammatory TME cultures, HCT116 cells showed strong nuclear labeling for
p65-NF-κB around 91% and slight cytoplasmic labeling (Figure 4), compared to HCT116 cells in
the basal control (87%) with a slightly lower expression of p65-NF-κB. In contrast, Calebin A in
the multicellular pro-inflammatory TME cultures inhibited distinctly nucle r staining and nuclear
translocation of p65-NF-κB in CRC cells in a dose-depend nt fashion by around 71% and 84% (Calebin A
1, 5 µM) compared to the control TME cultures (Figure 4).
Si ce phosphorylation and degradation of IκBα require activation of IκB kinase (IKK),
we investigated the capacity of BMS-345541, a specific IKK blocker, on TME-promoted IKK activity.
Interestingly, treatment of HCT116 cells in multicellular TME with BMS-345541 significantly inhibited
p65-NF-κB nuclear translocation, depending on the dose, by around 85% and 95% (5, 10 µM) compared
to the control TME cultures (Figure 4). The additional investigation of apoptosis stimulation with
DAPI staining revealed minimal apoptotic morphological changes in untreated cells in multicellular
TME (5%). In accordance with the phospho-p65 translocation data, treatment with Calebin A or
BMS-345541 alone significantly increased apoptotic morphological changes in alginate HCT116 cells in
multicellular pro-inflammatory TME with 50% to 70% apoptotic cells in HCT116 treated with Calebin A
(1, 5 µM) and with around 50% apoptotic cells in HCT116 treated with BMS-345541 (5, 10 µM) (Figure 4).
These findings show that the IKK is an important regulating upstream kinase and is essential for the
cytokine-NF-κB-mediated axis signaling pathway.
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Figure 4. Effect of Calebin A (CA) or specific IKK inhibitor BMS-345541 on activation and nuclear
translocation of p65-NF-κB in CRC cells: Serum-starved HCT116 cells in a monolayer culture from
multicellular pro-inflammatory TME cultures were treated as described in Materials and Methods,
stained for p65 subunit of NF-κB by immunofluorescence and counterstained with DAPI. Magnification
600×; scale bar = 30 mm. All experiments were performed at least in triplicate and quantification
of positively labelled p65-NF-κB-nuclei and apoptotic nuclei (white arrows) were performed by
counting 600–800 cells from 20 different microscopic fields. Values were compared with the control and
p < 0.05 (*), p < 0.01 (**) were considered statistically significant.
3.4. Calebin A Represses TME-Induced NF-κB Activation and NF-κB-Dependent Gene End-Products Involved
in Cell Proliferation, Invasion, and Apoptosis in CRC Cells
It has been reported that cytokines and pro-inflammatory TME promote the phosphorylation of
NF-κB and the expression of proliferative (cyclin D1), metastatic (MMP-9, CXCR4) tumor-promoting
proteins and inhibit apoptosis (caspase-3), which have a p65-NF-κB binding site in their
promoters [48–53]. The 3D-alginate cultures of HCT116 cells in multicellular TME were left untreated,
or treated with Calebin A or BMS-34554, as described in the Materials and Method section. It was
investigated whether Calebin A blocks the pro-inflammatory multicellular TME-induced activation of
p65-NF-κB and the expression of the above-mentioned p65-NF-κB-dependent proteins. The results
of the Western blot analysis showed that pro-inflammatory multicellular TME up-regulated the
expression of all these proteins (p65-NF-κB, cyclin D1, MMP-9 and CXCR4), and down-regulated
activated caspase-3. However, Calebin A, similar to IKK inhibitor (BMS-345541), suppressed them
(p65-NF-κB, cyclin D1, MMP-9 and CXCR4) and up-regulated activated caspase-3 in a dose-dependent
fashion, compared with those from the TME control group (Figure 5). These findings provide evidence
for the important capacity of Calebin A in suppressing the activation of TME-promoted NF-κB and
the expression of NF-κB-dependent gene products. In summary, these results suggest that one main
and important TME-pat wa promotes tum rigenesis in CRC cells by inducing the NF-κB s g aling
pathway. In addition, the anti-tumorigeni mpact of Calebin A is, at least in part, mediated by the
up-stream suppressi n f this pathway, similar to the inhibition of the NF-κB signaling pa hway
by BMS-345541.
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Figure 5. Effect of Calebin A (CA) or specific IKK inhibitor BMS-345541 on activation of NF-κB
and NF-κB-regulated gene end-products in CRC cells: Serum-starved HCT116 cells in alginate
cultures from multicellular pro-inflammatory TME cultures were treated as described in Materials
and Methods. Immunoblotting of whole-cell lysates from HCT116 was performed for anti-p65-NF-κB,
anti-phospho-p65-NF-κB, anti-MMP-9, anti-CXCR4, anti-Cyclin D1, and anti-cleaved-caspase-3.
β-actin served as an internal loading control in all experiments. For densitometric evaluation,
results are compared to control and p < 0.05 (*), p < 0.01 (**) were considered statistically significant.
3.5. Calebin A Reduces TME-Induced NF-κB-Dependent Anti-Apoptotic Gene Biomarkers in CRC Cells
It is known that the pro-inflammatory transcription factor NF-κB promotes and stimulates the
expression f anti-apoptotic biomarkers (tumor-promoting proteins) such as survivin, Bcl-2, and
Bcl-xL [54–61]. Therefore, we investigated whether Calebin A can modulate the pro-inflammatory,
multicellular TME-promoted expression of the aforementioned NF-κB-regulated anti-apopt tic
gene biomarkers. We foun that pro-inflammatory multicellular TME induces the ex ression of
all the above-mentioned anti-apoptotic biomarkers. Conversely, Calebin A, similar to the IKK
inhibitor (BMS-345541), represses pro-inflammatory multicellular TME-induced expression of these
cancer-promoting proteins in a dose-dependent fashion (Figure 6).
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anti-apoptotic gene products in CRC cells: Serum-starved HCT116 cells in alginate cultures from
multice lular pro-inflam atory TME cult ere treated as described in Materials and Methods.
Immunoblotting of whole-cell ysates from as performed for anti-survivi , anti-Bcl-2, and
anti-Bcl-xL in HCT116 cells. Densito tric values w re compared with the control and p < 0.05 (*),
p < 0.01 (**) were considered statistically significant. β-actin was used as an internal loading control.
3.6. Calebin A Disturbs the Direct Interaction of κ ith DNA in CR Cells
It has been previously reported that some specific NF-κB blockers suppress the activation of
the NF-κB pathway by interaction and modulation of NF-κB-subunits proteins, thereby inhibiting
its interaction with DNA [40,62–64]. We analyzed whether Calebin A is able to trigger the inhibition
of NF-κB activation in CRC cells in multicellular pro-inflammatory TME by a related pathway.
To determine this, we incubated extracted nuclei from multicellular pro-inflammatory TME HCT116
cells with or without Calebin A as described in Materials and Methods. As shown in Figure 7A,
Calebin A significantly blocked NF-κB int raction with DNA in a dose-dependent fashion. Since the
cysteine groups at the 38 position in p65 subunit of NF-κB are mainly associated wit their attraction
to DNA, we performed the test for the re uction in cysteine groups by DTT in the presence or absence of
Calebin A, as described in the section Materials and Methods. We found that the inhibition capacity of
Calebin A on the p65-NF-κB binding to the DNA was reversed by DTT in HCT116 nuclei, underlining
that Calebin A specifically modulates the binding of p65-NF-κB to DNA (Figure 7B). Collectively, these
findings suggest that the modulation of this essential binding may be one of the most critical molecular
signaling steps of multi-targeted Calebin A, as it inhibits p65-NF-κB stimulation.
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Figure 7. Direct effect of Calebin A (CA) on NF-κB binding to DNA in CRC cells: Serum-starved
HCT116 cells in alginate cultures from multicellular pro-inflammatory TME cultures were treated as
described in Materials and Methods. A: Isolated nuclei from basal control HCT116 cells or HCT116
cells from multicellular TME, incubated ith the indicated concentrations of Calebin A for 30 min,
nuclear extracts were pr par d and then immunoblotted for p65-NF-κB activation by Western blotting.
PARP served as an internal loadi g control all exper ments. B: Isola ed nuclei from HCT116 basal
control or multicellular TME, in ubated for 30 min with 5 µM Calebin A in the presenc or absence of
5 mM DTT, nuclear extracts were prepared and then probed for p65-NF-κB binding to DNA by Western
blotting. PARP served as an internal loading control in all experiments.
Biomedicines 2020, 8, 236 11 of 17
4. Discussion
In this study, we evaluated the molecular pathway by which Calebin A exerts its anti-inflammatory,
anti-proliferative, and anti-tumor activity in a multicellular pro-inflammatory TME. We could show
that Calebin A suppresses the master pro-inflammatory transcription factor NF-κB by inhibiting
phosphorylation, and its translocation into the nucleus, which is promoted by the TME. Furthermore,
Calebin A blocked the interaction of p65-NF-κB with DNA. In this way, Calebin A down-modulated
NF-κB-promoting gene end-products involved in invasion, proliferation, and anti-apoptosis, ultimately
triggering the induction of apoptosis, which was down-regulated by the TME (Figure 8).
Biomedicines 2020, 8, x FOR PEER REVIEW 11 of 17 
or absence of 5 mM DTT, nuclear extracts were prepared and then probed for p65-NF-B binding to 
DNA by Western blotting. PARP served as an internal loading control in all experiments. 
. isc ssi  
I  this study, we evaluated the molecular path ay by which Calebin A exerts its anti-
inflammatory, anti-proliferative, and anti-tumor activity in a multicellul r pro-inflammatory TME. 
We could show that Calebin A suppresses the master pro-inflammat ry transcription factor NF-B 
by inhibiting phosphorylation, and its translocation into t e nucleus, which is promoted by t  TME. 
Furthermore, Calebin A blocked the interaction of p65-NF-B with DNA. In this way, Calebin A 
down-modulated NF-B-promoting gene en -products involved in i v sion, proliferation, and nti-
apoptosis, ultimately triggering the induction of apoptosis, which was down-regulated by the TME 
(Figure 8). 
 
Figure 8. Modulatory impacts of Calebin A on the NF-B signaling pathway in the multicellular TME. 
In the present study, we have developed a novel 3D TME culture-system consisting of tumor 
cells (3D-alginate), T-lymphocytes, and fibroblasts to better understand and mimic the in vivo 
heterogeneous pro-inflammatory TME (Figure 1). In fact, it has been reported that fibroblasts are the 
main active cells of the tumor stroma in TME and are involved in promoting tumor progression by 
secreting tumor stimulating proteins, extracellular matrix, and enzymes [65,66]. Here, we evaluated, 
for the first time, the suppression effect of Calebin A on the NF-B signaling and NF-B-regulated 
cellular responses in detail on HCT116 CRC cells in alginate cultures in this TME. It is well established 
that NF-B acts as a master regulator of inflammation and is closely associated with inflammatory 
reactions and chronic diseases, including cancer and TME [15,20,67,68]. Moreover, it has been shown 
that the various inflammatory responses stimulate the interaction of tumor cells and the stroma in 
the TME [11,24], however, the cell-specific and inflammation-induced molecular pathways that allow 
cancer cells to proliferate and metastasize in the TME are not fully described. In the TME, the 
constitutive activation of NF-B promotes the survival and proliferation of tumor cells and stimulates 
the inappropriate activation of immune cells, which leads to the escape of tumor cells from apoptotic 
mechanisms [11]. It is well documented that the TME is infiltrated by a wide range of immune cell 
populations [69], and recent data suggest that immune cell infiltrates may also affect prognosis in 
CRC [70]. However, whether immune cell infiltrates in the TME could have a poor or improved 
prognosis remains controversial [11]. Interestingly, it has been suggested that the activation of the 
NF-B signaling pathway plays a key role not only in the activation of signal transduction in cancer 
cells, but also in the recruitment of infiltrating leukocytes in the TME [71]. In fact, NF-B enhances 
cross-talk with the TME containing cells and the stromal and inflammatory cells, through the up-
regulation of pro-inflammatory cytokines, such as TNF-α [72]. In acute lymphoblastic leukemia (T-
ALL) of T cells, the inhibition of the NF-B signaling pathway could suppress tumor growth both in 
the in vitro and the in vivo settings [73]. Interestingly, in a mouse colitis model it was shown that the 
deletion of IKK in intestinal epithelial cells down-regulated expression of pro-inflammatory 
cytokines, highlighting the crucial role of inflammation in supporting cancer and indicating that 
specific blocking of the pro-inflammatory IKK/NF-B pathway may be an attractive and promising 
Figure 8. odulatory i pacts of alebin on the F-κB signaling path ay in the ulticellular T E.
present study, we have dev loped a novel 3D TME culture-system consisting of tumor cells
(3D-alginate), T-lymphocytes, and fibroblasts to better unders and a mimic the in vivo heterogeneous
pro-inflammatory TME (Figure 1). In fact, it has been reported that fibroblasts are the main activ
cells of he tumor s roma in TME and are involved in promoti g tu r progression by secreting
tumor stimulating prote s, extracellula matrix, and enzymes [65,66]. Here, we valuat d, for the
first time, the suppr ssion effect of Calebin A on the NF-κB signaling a d NF-κB-regulated cellular
r sponses in deta l on HCT116 CRC cells in alginate cultures in this TME. It is wel
κ fl fl
ri s infla atory responses stimulate the interaction of tumor cells and the stroma
in the TME [11,24], however, the cell-specific and inflammation-in uced molecular pathw ys that
allow cancer cells to p oliferate and metastasize in the TME are not fully described. In the E,
κ
It l t t t fi
fi ff
o ever, ether i une ce l i filtrates i t l
I ter sti ly,
κ i aling pathway plays a key role not nly in the activation f signal tr nsduction in cancer cells,
but also in the recruitment of infiltrat g leukocyt s in the TME [71]. In fact, NF-κB enhances cross-talk
with the TME containing ells a d the stromal and inflammatory cells, thr ugh the up-re ulation of
pro-inflammatory cytokines, such as TNF-α [72]. In acute lymphoblastic eukemia (T-ALL) of T cells,
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On the basis of our findings, we suggest that this 3D-multicellular pro-inflammatory TME model could
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also be useful for the testing and screening of various types of tumor, therapeutic agents/drugs, and for
the investigation of different therapeutic targets.
In a similar way to BMS-345541 (a specific pharmacological highly selective inhibitor of IKK) [46]
Calebin A displayed its cytotoxic and anti-proliferative activities in the multicellular pro-inflammatory
TME. It was evidenced through MTT assay and confirmed by colonosphere and invasion assays.
In addition, these specific anti-tumor actions of Calebin A further correlated with inhibition of cell
metastatic (CXCR4, MMP-9) and proliferative (cyclin D1) biomarkers, all of which are known to
have a NF-κB binding site in their promoters, thus promoting their transcription. These results are
consistent with our previous reports with various other natural products such as turmeric [25,40,75]
and resveratrol [26,27,76,77]. Moreover, Calebin A, similar to BMS-345541, reduced the multicellular
pro-inflammatory TME-stimulated phosphorylation and translocation of the p65 subunit of NF-κB
from the cytoplasm to the nucleus, suggesting that Calebin A, which possesses pro-apoptotic properties,
has the potential to prevent tumor invasion and proliferation, at least in part, by up-stream targeting
the IKK-NF-κB signaling pathway. In fact, it has been reported that the down-modulation of
p65-NF-κB in cancer cells at different levels of the signaling pathway increases the benefits for
therapeutic approaches [27,78]. To the best of our knowledge, this is the first study to date to show
the anti-inflammatory and anti-tumor impacts of Calebin A on multicellular pro-inflammatory TME,
at least in part through targeting the suppression of the NF-κB signaling pathway.
We also found that Calebin A blocked the direct interaction between p65-NF-κB and DNA,
indicating its specific targeting and modulation capacity of the p65-NF-κB protein. Previous studies
have demonstrated that p65-NF-κB subunits with its cysteine38 residue are responsible for the
interaction between NF-κB and DNA [79]. Blocking this specific interaction by Calebin A could
be inhibited by a reducing agent, such as DTT, suggesting that Calebin A may modulate cysteine
residues in the p65-NF-κB subunit. In fact, this finding is consistent with a large body of evidence
that has previously shown that numerous active ingredients such as caffeic acid, phenethyl ester [63],
plumbagin [64], thymoquinone [80], sesquiterpene lactone parthenolide [79], and Calebin A have a
similar action [37,40]. However, this result shows for the first time that Calebin A inhibits multicellular
pro-inflammatory TME-promoted NF-κB stimulation by direct blocking between p65-NF-κB and
DNA, and this may be one of the most essential molecular mechanisms of Calebin A, as it blocks
p65-NF-κB stimulation. Based on our results, we assume that specific NF-κB activation in tumor
cells was precisely associated with the development of this multicellular pro-inflammatory TME by
promoting proliferation, colonosphere formation, and invasion ability. Furthermore, these results clearly
indicate a functional relationship between the NF-κB signaling pathway and the inflammation-induced
aggressiveness of CRC.
We found that multicellular pro-inflammatory TME promoted NF-κB activation, which in turn
mediated the inhibition of apoptosis by the expression of various anti-apoptotic gene biomarkers, which
indicate a driving function of NF-κB in the TME-stimulated augmentation of CRC cell malignancy.
In addition, we have shown that Calebin A, similar to BMS-345541, decreased the expression of
survivin, Bcl-2, and Bcl-xL proteins. As a matter of fact, it has been previously reported that other
natural compounds suppress the anti-apoptotic proteins in human CRC cells [81,82]. Furthermore, we
have shown that Calebin A, similar to BMS-345541, induced apoptosis through the activation of
the apoptotic NF-κB-regulated gene biomarker, caspase-3 and the increasing of pyknosis, chromatin
condensation, and apoptotic body formation. Based on these data, we could clearly demonstrate that
this mixed heterogeneous pro-inflammatory TME with NF-κB up-regulation is a suitable functional
paracrine transmitter of CRC tumorigenesis in vitro.
Overall, our findings illustrated that Calebin A significantly suppressed NF-κB activation and
NF-κB-promoted anti-apoptotic biomarkers, making it a potentially effective inhibitor of inflammation,
proliferation, invasion, and survival of cancer cells.
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5. Conclusions
To conclude, our results indicate a crucial positive interaction between stroma cells and CRC cells
in this multicellular pro-inflammatory TME, which is essential for the induction of CRC cells tumor
progression, proliferation, and invasion. Furthermore, Calebin A has a significant anti-inflammatory
potential and it down-regulates multicellular TME-induced tumor malignancy by specific targeting
the p65-NF-κB signaling pathway, leading to suppressed proliferation and induction of apoptosis.
Our results underline further that the NF-κB signaling pathway may be a potential therapeutic target
for CRC treatment. Further studies on Calebin A could provide important information for potential
applications within combination therapies in the management of cancer and other chronic diseases.
Author Contributions: Conceptualization, C.B., P.S., and M.S.; supervision, M.S.; methodology, C.B., P.S., K.B.,
A.B.K., P.K., and L.K.; formal analysis, M.S.,P.K., and A.B.K.; visualization, C.B. and P.S.; writing—original draft,
M.S. and C.B.; writing—review and editing, C.B., P.S., K.B., A.B.K., P.K., L.K., and M.S.; project administration,
M.S. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Acknowledgments: We would like to thank Sabine Miech and Andreas Eimannsberger for excellent
technical assistance.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Siegel, R.L.; Miller, K.D.; Goding Sauer, A.; Fedewa, S.A.; Butterly, L.F.; Anderson, J.C.; Cercek, A.; Smith, R.A.;
Jemal, A. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 145–164. [CrossRef] [PubMed]
2. Kuipers, E.J.; Grady, W.M.; Lieberman, D.; Seufferlein, T.; Sung, J.J.; Boelens, P.G.; van de Velde, C.J.;
Watanabe, T. Colorectal cancer. Nat. Rev. Dis. Primers. 2015, 1, 15065. [CrossRef] [PubMed]
3. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer
J. Clin. 2018, 68, 394–424. [CrossRef] [PubMed]
4. Dekker, E.; Tanis, P.J.; Vleugels, J.L.A.; Kasi, P.M.; Wallace, M.B. Colorectal cancer. Lancet 2019, 394, 1467–1480.
[CrossRef]
5. Emon, B.; Bauer, J.; Jain, Y.; Jung, B.; Saif, T. Biophysics of Tumor Microenvironment and Cancer Metastasis:
A Mini Review. Comput. Struct. Biotechnol. J. 2018, 16, 279–287. [CrossRef]
6. Roma-Rodrigues, C.; Mendes, R.; Baptista, P.V.; Fernandes, A.R. Targeting Tumor Microenvironment for
Cancer Therapy. Int. J. Mol. Sci. 2019, 20, 840. [CrossRef]
7. Storz, P.; Crawford, H.C. Carcinogenesis of Pancreatic Ductal Adenocarcinoma. Gastroenterol. 2020, 158,
2072–2081. [CrossRef]
8. Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 2016, 16, 582–598. [CrossRef]
9. Mantovani, A.; Marchesi, F.; Malesci, A.; Laghi, L.; Allavena, P. Tumour-associated macrophages as treatment
targets in oncology. Nat. Rev. Clin. Oncol. 2017, 14, 399–416. [CrossRef]
10. Cortese, N.; Donadon, M.; Rigamonti, A.; Marchesi, F. Macrophages at the crossroads of anticancer strategies.
Front. Biosci. (Landmark Ed.) 2019, 24, 1271–1283.
11. Whiteside, T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27,
5904–5912. [CrossRef] [PubMed]
12. Colombo, F.; Zambrano, S.; Agresti, A. NF-kappaB, the Importance of Being Dynamic: Role and Insights in
Cancer. Biomedicines 2018, 6, 45. [CrossRef] [PubMed]
13. Xia, L.; Tan, S.; Zhou, Y.; Lin, J.; Wang, H.; Oyang, L.; Tian, Y.; Liu, L.; Su, M.; Wang, H.; et al. Role of the
NFkappaB-signaling pathway in cancer. Oncotargets Ther. 2018, 11, 2063–2073. [CrossRef] [PubMed]
14. Park, M.H.; Hong, J.T. Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic
Approaches. Cells 2016, 5, 15. [CrossRef]
15. Aggarwal, B.B. Nuclear factor-kappaB: The enemy within. Cancer Cell. 2004, 6, 203–208. [CrossRef]
16. Kearns, J.D.; Basak, S.; Werner, S.L.; Huang, C.S.; Hoffmann, A. IkappaBepsilon provides negative feedback
to control NF-kappaB oscillations, signaling dynamics, and inflammatory gene expression. J. Cell Biol. 2006,
173, 659–664. [CrossRef]
Biomedicines 2020, 8, 236 14 of 17
17. Karin, M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441, 431–436.
[CrossRef]
18. Inoue, J.; Gohda, J.; Akiyama, T.; Semba, K. NF-kappaB activation in development and progression of cancer.
Cancer Sci. 2007, 98, 268–274. [CrossRef]
19. Schottelius, A.J.; Dinter, H. Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer.
Cancer Treat. Res. 2006, 130, 67–87. [CrossRef]
20. Bharti, A.C.; Aggarwal, B.B. Nuclear factor-kappa B and cancer: Its role in prevention and therapy.
Biochem. Pharmacol. 2002, 64, 883–888. [CrossRef]
21. Yu, L.L.; Yu, H.G.; Yu, J.P.; Luo, H.S.; Xu, X.M.; Li, J.H. Nuclear factor-kappaB p65 (RelA) transcription factor
is constitutively activated in human colorectal carcinoma tissue. World J. Gastroenterol. 2004, 10, 3255–3260.
[CrossRef] [PubMed]
22. Karin, M.; Lin, A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 2002, 3, 221–227. [CrossRef]
[PubMed]
23. Jani, T.S.; DeVecchio, J.; Mazumdar, T.; Agyeman, A.; Houghton, J.A. Inhibition of NF-kappaB signaling
by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J. Biol. Chem. 2010, 285,
19162–19172. [CrossRef] [PubMed]
24. Aggarwal, B.B.; Gehlot, P. Inflammation and cancer: How friendly is the relationship for cancer patients?
Curr. Opin. Pharmacol. 2009, 9, 351–369. [CrossRef]
25. Buhrmann, C.; Popper, B.; Kunnumakkara, A.B.; Aggarwal, B.B.; Shakibaei, M. Evidence That Calebin
A, a Component of Curcuma Longa Suppresses NF-B Mediated Proliferation, Invasion and Metastasis of
Human Colorectal Cancer Induced by TNF-beta (Lymphotoxin). Nutrients 2019, 11, 2904. [CrossRef]
26. Buhrmann, C.; Yazdi, M.; Popper, B.; Kunnumakkara, A.B.; Aggarwal, B.B.; Shakibaei, M. Induction of the
Epithelial-to-Mesenchymal Transition of Human Colorectal Cancer by Human TNF-beta (Lymphotoxin) and
its Reversal by Resveratrol. Nutrients 2019, 11, 704. [CrossRef]
27. Buhrmann, C.; Yazdi, M.; Popper, B.; Shayan, P.; Goel, A.; Aggarwal, B.B.; Shakibaei, M. Evidence that
TNF-beta induces proliferation in colorectal cancer cells and resveratrol can down-modulate it. Exp. Biol. Med.
2019, 244, 1–12. [CrossRef]
28. Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 2009, 9, 361–371. [CrossRef]
29. Yang, J.G.; Wang, W.M.; Xia, H.F.; Yu, Z.L.; Li, H.M.; Ren, J.G.; Chen, G.; Wang, B.K.; Jia, J.;
Zhang, W.; et al. Lymphotoxin-alpha promotes tumor angiogenesis in HNSCC by modulating glycolysis in a
PFKFB3-dependent manner. Int. J. Cancer 2019, 145, 1358–1370. [CrossRef]
30. Soleimani, A.; Rahmani, F.; Ferns, G.A.; Ryzhikov, M.; Avan, A.; Hassanian, S.M. Role of the NF-κB signaling
pathway in the pathogenesis of colorectal cancer. Gene 2020, 726, 144132. [CrossRef]
31. Huang, X.M.; Yang, Z.J.; Xie, Q.; Zhang, Z.K.; Zhang, H.; Ma, J.Y. Natural products for treating colorectal
cancer: A mechanistic review. Biomed. Pharm. 2019, 117, 109142. [CrossRef] [PubMed]
32. Cheng, Y.T.; Yang, C.C.; Shyur, L.F. Phytomedicine-Modulating oxidative stress and the tumor
microenvironment for cancer therapy. Pharm. Res. 2016, 114, 128–143. [CrossRef] [PubMed]
33. Casey, S.C.; Amedei, A.; Aquilano, K.; Azmi, A.S.; Benencia, F.; Bhakta, D.; Bilsland, A.E.; Boosani, C.S.;
Chen, S.; Ciriolo, M.R.; et al. Cancer prevention and therapy through the modulation of the tumor
microenvironment. Semin. Cancer Biol. 2015, 35, s199–s223. [CrossRef]
34. Nair, A.; Amalraj, A.; Jacob, J.; Kunnumakkara, A.B.; Gopi, S. Non-Curcuminoids from Turmeric and
Their Potential in Cancer Therapy and Anticancer Drug Delivery Formulations. Biomolecules. 2019, 9, 13.
[CrossRef] [PubMed]
35. Aggarwal, B.B.; Yuan, W.; Li, S.; Gupta, S.C. Curcumin-free turmeric exhibits anti-inflammatory and
anticancer activities: Identification of novel components of turmeric. Mol. Nutr. Food Res. 2013, 57, 1529–1542.
[CrossRef]
36. Gupta, S.C.; Sung, B.; Kim, J.H.; Prasad, S.; Li, S.; Aggarwal, B.B. Multitargeting by turmeric, the golden
spice: From kitchen to clinic. Mol. Nutr. Food Res. 2013, 57, 1510–1528. [CrossRef] [PubMed]
37. Tyagi, A.K.; Prasad, S.; Majeed, M.; Aggarwal, B.B. Calebin A, a novel component of turmeric, suppresses
NF-kappaB regulated cell survival and inflammatory gene products leading to inhibition of cell growth and
chemosensitization. Phytomedicine: Int. J. Phytother. Phytopharm. 2017, 34, 171–181. [CrossRef]
Biomedicines 2020, 8, 236 15 of 17
38. Li, Y.; Li, S.; Han, Y.; Liu, J.; Zhang, J.; Li, F.; Wang, Y.; Liu, X.; Yao, L. Calebin-A induces apoptosis and
modulates MAPK family activity in drug resistant human gastric cancer cells. Eur. Pharmacol. 2008, 591,
252–258. [CrossRef]
39. Lee, M.J.; Tsai, Y.J.; Lin, M.Y.; You, H.L.; Kalyanam, N.; Ho, C.T.; Pan, M.H. Calebin-A induced death of
malignant peripheral nerve sheath tumor cells by activation of histone acetyltransferase. Phytomedicine: Int.
J. Phytother. Phytopharm. 2019, 57, 377–384. [CrossRef]
40. Buhrmann, C.; Kunnumakkara, A.B.; Popper, B.; Majeed, M.; Aggarwal, B.B.; Shakibaei, M. Calebin A
Potentiates the Effect of 5-FU and TNF-beta (Lymphotoxin alpha) against Human Colorectal Cancer Cells:
Potential Role of NF-kappaB. Int. J. Mol. Sci. 2020, 21, 2393. [CrossRef]
41. Shakibaei, M.; Kraehe, P.; Popper, B.; Shayan, P.; Goel, A.; Buhrmann, C. Curcumin potentiates antitumor
activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. BMC. Cancer 2015,
15, 250. [CrossRef] [PubMed]
42. Shakibaei, M.; Sung, B.; Sethi, G.; Aggarwal, B.B. TNF-alpha-induced mitochondrial alterations in human T
cells requires FADD and caspase-8 activation but not RIP and caspase-3 activation. Antioxid. Redox Signal.
2010, 13, 821–831. [CrossRef] [PubMed]
43. Shakibaei, M.; De Souza, P. Differentiation of mesenchymal limb bud cells to chondrocytes in alginate beads.
Cell Biol. Int. 1997, 21, 75–86. [CrossRef] [PubMed]
44. Baichwal, V.R.; Baeuerle, P.A. Activate NF-kappa B or die? Curr. Biol. 1997, 7, R94–R96. [CrossRef]
45. Shishodia, S.; Aggarwal, B.B. Nuclear factor-kappaB activation: A question of life or death. J. Biochem.
Mol. Biol. 2002, 35, 28–40. [CrossRef] [PubMed]
46. Burke, J.R.; Pattoli, M.A.; Gregor, K.R.; Brassil, P.J.; MacMaster, J.F.; McIntyre, K.W.; Yang, X.; Iotzova, V.S.;
Clarke, W.; Strnad, J.; et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an
allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J. Biol. Chem. 2003,
278, 1450–1456. [CrossRef]
47. Ghosh, S.; May, M.J.; Kopp, E.B. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of
immune responses. Annu. Rev. Immunol. 1998, 16, 225–260. [CrossRef]
48. Duyao, M.P.; Kessler, D.J.; Spicer, D.B.; Bartholomew, C.; Cleveland, J.L.; Siekevitz, M.; Sonenshein, G.E.
Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NF kappa B.
J. Biol. Chem. 1992, 267, 16288–16291.
49. Estève, P.O.; Chicoine, E.; Robledo, O.; Aoudjit, F.; Descoteaux, A.; Potworowski, E.F.; St-Pierre, Y. Protein
kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-alpha
in glioma cells via NF-kappa B. J. Biol. Chem. 2002, 277, 35150–35155. [CrossRef]
50. Guttridge, D.C.; Albanese, C.; Reuther, J.Y.; Pestell, R.G.; Baldwin, A.S., Jr. NF-kappaB controls cell growth
and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 1999, 19, 5785–5799.
[CrossRef]
51. Van de Stolpe, A.; Caldenhoven, E.; Stade, B.G.; Koenderman, L.; Raaijmakers, J.A.; Johnson, J.P.;
van der Saag, P.T. 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction
of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human
intercellular adhesion molecular-1 promoter. J. Biol. Chem. 1994, 269, 6185–6192. [PubMed]
52. Yamamoto, K.; Arakawa, T.; Ueda, N.; Yamamoto, S. Transcriptional roles of nuclear factor kappa B and
nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in
MC3T3-E1 cells. J. Biol. Chem. 1995, 270, 31315–31320. [CrossRef] [PubMed]
53. Zhou, G.; Kuo, M.T. NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells.
J. Biol. Chem. 1997, 272, 15174–15183. [CrossRef] [PubMed]
54. Zhu, L.; Fukuda, S.; Cordis, G.; Das, D.K.; Maulik, N. Anti-apoptotic protein survivin plays a significant
role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning.
FEBS. Lett. 2001, 508, 369–374. [CrossRef]
55. Schwenzer, R.; Siemienski, K.; Liptay, S.; Schubert, G.; Peters, N.; Scheurich, P.; Schmid, R.M.; Wajant, H.
The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by
cytokines of the TNF ligand family and modulates TNF-induced activation of NF-kappaB and c-Jun
N-terminal kinase. J. Biol. Chem. 1999, 274, 19368–19374. [CrossRef]
Biomedicines 2020, 8, 236 16 of 17
56. Chu, Z.L.; McKinsey, T.A.; Liu, L.; Gentry, J.J.; Malim, M.H.; Ballard, D.W. Suppression of tumor necrosis
factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc. Natl. Acad.
Sci. USA 1997, 94, 10057–10062. [CrossRef]
57. You, M.; Ku, P.T.; Hrdlicková, R.; Bose, H.R., Jr. ch-IAP1, a member of the inhibitor-of-apoptosis protein
family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. Mol. Cell. Biol. 1997, 17, 7328–7341.
[CrossRef]
58. Stehlik, C.; de Martin, R.; Kumabashiri, I.; Schmid, J.A.; Binder, B.R.; Lipp, J. Nuclear factor
(NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor
necrosis factor alpha-induced apoptosis. J. Exp. Med. 1998, 188, 211–216. [CrossRef]
59. Grumont, R.J.; Rourke, I.J.; Gerondakis, S. Rel-dependent induction of A1 transcription is required to protect
B cells from antigen receptor ligation-induced apoptosis. Genes Dev. 1999, 13, 400–411. [CrossRef]
60. Kreuz, S.; Siegmund, D.; Scheurich, P.; Wajant, H. NF-kappaB inducers upregulate cFLIP,
a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell. Biol. 2001, 21, 3964–3973.
[CrossRef]
61. Tamatani, M.; Che, Y.H.; Matsuzaki, H.; Ogawa, S.; Okado, H.; Miyake, S.; Mizuno, T.; Tohyama, M.
Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary
hippocampal neurons. J. Biol. Chem. 1999, 274, 8531–8538. [CrossRef] [PubMed]
62. Mahon, T.M.; O’Neill, L.A. Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-kappa
B activation in T lymphocytes. Evidence for covalent modification of the p50 subunit. J. Biol. Chem. 1995,
270, 28557–28564. [CrossRef] [PubMed]
63. Natarajan, K.; Singh, S.; Burke, T.R., Jr.; Grunberger, D.; Aggarwal, B.B. Caffeic acid phenethyl ester is a
potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc. Natl. Acad.
Sci. USA 1996, 93, 9090–9095. [CrossRef]
64. Sandur, S.K.; Ichikawa, H.; Sethi, G.; Ahn, K.S.; Aggarwal, B.B. Plumbagin (5-hydroxy-2-methyl-1,4-
naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through
modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by
cytokine and chemotherapeutic agents. J. Biol. Chem. 2006, 281, 17023–17033. [CrossRef] [PubMed]
65. Luga, V.; Zhang, L.; Viloria-Petit, A.M.; Ogunjimi, A.A.; Inanlou, M.R.; Chiu, E.; Buchanan, M.; Hosein, A.N.;
Basik, M.; Wrana, J.L. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast
cancer cell migration. Cell 2012, 151, 1542–1556. [CrossRef]
66. Orimo, A.; Weinberg, R.A. Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 2006,
5, 1597–1601. [CrossRef]
67. Ding, G.J.; Fischer, P.A.; Boltz, R.C.; Schmidt, J.A.; Colaianne, J.J.; Gough, A.; Rubin, R.A.; Miller, D.K.
Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin-1 and tumor
necrosis factor-alpha. Development and use of a high capacity fluorescence cytometric system. J. Biol. Chem.
1998, 273, 28897–28905. [CrossRef]
68. Ghosh, S.; Karin, M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109, S81–S96. [CrossRef]
69. Balkwill, F.; Mantovani, A. Inflammation and cancer: Back to Virchow? Lancet 2001, 357, 539–545. [CrossRef]
70. Pagès, F.; Berger, A.; Camus, M.; Sanchez-Cabo, F.; Costes, A.; Molidor, R.; Mlecnik, B.; Kirilovsky, A.;
Nilsson, M.; Damotte, D.; et al. Effector memory T cells, early metastasis, and survival in colorectal cancer.
N. Engl. J. Med. 2005, 353, 2654–2666. [CrossRef]
71. Balkwill, F.; Coussens, L.M. Cancer: An inflammatory link. Nature 2004, 431, 405–406. [CrossRef] [PubMed]
72. Pikarsky, E.; Porat, R.M.; Stein, I.; Abramovitch, R.; Amit, S.; Kasem, S.; Gutkovich-Pyest, E.; Urieli-Shoval, S.;
Galun, E.; Ben-Neriah, Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer.
Nature 2004, 431, 461–466. [CrossRef] [PubMed]
73. Vilimas, T.; Mascarenhas, J.; Palomero, T.; Mandal, M.; Buonamici, S.; Meng, F.; Thompson, B.; Spaulding, C.;
Macaroun, S.; Alegre, M.L.; et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell
leukemia. Nat. Med. 2007, 13, 70–77. [CrossRef] [PubMed]
74. Greten, F.R.; Eckmann, L.; Greten, T.F.; Park, J.M.; Li, Z.W.; Egan, L.J.; Kagnoff, M.F.; Karin, M. IKKbeta
links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118, 285–296.
[CrossRef] [PubMed]
Biomedicines 2020, 8, 236 17 of 17
75. Kim, J.H.; Gupta, S.C.; Park, B.; Yadav, V.R.; Aggarwal, B.B. Turmeric (Curcuma longa) inhibits inflammatory
nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed
proliferation, induced chemosensitization, and suppressed osteoclastogenesis. Mol. Nutr. Food Res. 2012, 56,
454–465. [CrossRef]
76. Buhrmann, C.; Popper, B.; Aggarwal, B.B.; Shakibaei, M. Resveratrol downregulates inflammatory pathway
activated by lymphotoxin alpha (TNF-beta) in articular chondrocytes: Comparison with TNF-alpha.
PLoS ONE 2017, 12, e0186993. [CrossRef]
77. Buhrmann, C.; Yazdi, M.; Popper, B.; Shayan, P.; Goel, A.; Aggarwal, B.B.; Shakibaei, M. Resveratrol
Chemosensitizes TNF-beta-Induced Survival of 5-FU-Treated Colorectal Cancer Cells. Nutrients 2018, 10, 888.
[CrossRef]
78. Kumar, A.; Takada, Y.; Boriek, A.M.; Aggarwal, B.B. Nuclear factor-kappaB: Its role in health and disease.
J. Mol. Med. 2004, 82, 434–448. [CrossRef]
79. García-Piñeres, A.J.; Castro, V.; Mora, G.; Schmidt, T.J.; Strunck, E.; Pahl, H.L.; Merfort, I. Cysteine 38 in
p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem. 2001,
276, 39713–39720. [CrossRef]
80. Sethi, G.; Ahn, K.S.; Aggarwal, B.B. Targeting nuclear factor-kappa B activation pathway by thymoquinone:
Role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol. Cancer Res. 2008, 6,
1059–1070. [CrossRef]
81. Gali-Muhtasib, H.; Diab-Assaf, M.; Boltze, C.; Al-Hmaira, J.; Hartig, R.; Roessner, A.; Schneider-Stock, R.
Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a
p53-dependent mechanism. Int. J. Oncol. 2004, 25, 857–866. [PubMed]
82. Sethi, G.; Sung, B.; Aggarwal, B.B. TNF: A master switch for inflammation to cancer. Front. Biosci. 2008, 13,
5094–5107. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
